Summary：**AngioDynamics Soars 18% in Med Tech, Achieves Record 2026 Sales***Introduction* Shares of AngioDy

**AngioDynamics Soars 18% in Med Tech, Achieves Record 2026 Sales**

*Introduction*
Shares of AngioDynamics jumped 18% on Wednesday after the medical‑technology firm announced record‑setting sales for the fiscal year 2026. The surge reflects stronger demand for its minimally invasive vascular and oncology products, as well as optimism about the company’s expanding pipeline. Investors reacted swiftly, pushing the stock to its highest level in over a year and signaling renewed confidence in AngioDynamics’ ability to outperform a competitive med‑tech landscape.

*Key Developments*
The company reported 2026 revenue of $1.34 billion, a 12% increase over the previous year and the highest annual figure in its history. Growth was driven primarily by the NanoKnife® irreversible electroporation system, which saw a 22% rise in unit sales, and the Venclose™ endovenous treatment platform, which posted a 15% jump. AngioDynamics also highlighted a 9% increase in international sales, attributing the gain to successful launches in Europe and Asia‑Pacific markets. On the regulatory front, the FDA cleared a next‑generation catheter design for peripheral artery disease, expected to hit hospitals in mid‑2027.

*Industry Analysis*
AngioDynamics’ performance mirrors broader trends in the med‑tech sector, where firms that combine procedural efficiency with demonstrable clinical outcomes are capturing market share. According to a recent IQVIA report, the global minimally invasive device market is projected to grow at a CAGR of 6.8% through 2028, fueled by aging populations and a shift toward outpatient procedures. AngioDynamics’ focus on niche therapeutic areas—such as pancreatic cancer ablation and venous disease—allows it to avoid head‑on competition with larger conglomerates while commanding premium pricing. Analysts note that the company’s disciplined R&D spend, which rose to 7.5% of sales in 2026, is translating into a steady flow of patented innovations, a key differentiator in an industry where intellectual property often dictates long‑term viability.

*Future Outlook*
Management raised its 2027 revenue guidance to $1.45 billion, citing anticipated uptake of the newly cleared catheter and expansion